Abstract
Variants at the gene encoding for the 5-hydrosytryptamine (serotonin) receptor 2A (HTR2A) have been associated with many psychiatric disorders such as schizophrenia, mood disorders, attention deficit hyperactivity disorder, suicide, anxiety disorders, obsessive-compulsive disorder, eating disorders, and Alzheimers disease. The studied SNPs differ across studies, in the present review we focused on available evidence with the aim of identifying the overall phenotypic profile of HTR2A variant carriers. We then extensively analyzed all SNPs of the HTR2A gene with criteria of frequency, haplotype blocks, previous evidence, functionality in order to obtain a list of suitable SNPs for future studies that properly cover all possible genetic control of the HTR2A gene. Genetic association studies report conflicting and generally negative results. Most replicated data suggest C allele of the 102 T/C and Tyr452 variants as risk factor for psychosis and antipsychotic response, but the number of not replicating studies does not allow to draw any definite conclusion. Moreover their impact as risk factors is very small. In the other investigated psychiatric fields, evidence shows no involvement or at least a small and not replicated role for HTR2A gene variants. Conflicting and negative results could be due to a real marginal role of this receptor gene variants, or it could be caused by a lack of gene coverage of investigated SNPs. We suggest a wider investigation of the HTR2A gene to better understand its role in psychiatric disorders, preferably complemented with the use of proteomic or metabolomic approaches.
Keywords: Serotonin, psychiatry, schizophrenia, mood disorders, depression, gene
Current Medicinal Chemistry
Title: HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies
Volume: 14 Issue: 19
Author(s): Alessandro Serretti, Antonio Drago and Diana De Ronchi
Affiliation:
Keywords: Serotonin, psychiatry, schizophrenia, mood disorders, depression, gene
Abstract: Variants at the gene encoding for the 5-hydrosytryptamine (serotonin) receptor 2A (HTR2A) have been associated with many psychiatric disorders such as schizophrenia, mood disorders, attention deficit hyperactivity disorder, suicide, anxiety disorders, obsessive-compulsive disorder, eating disorders, and Alzheimers disease. The studied SNPs differ across studies, in the present review we focused on available evidence with the aim of identifying the overall phenotypic profile of HTR2A variant carriers. We then extensively analyzed all SNPs of the HTR2A gene with criteria of frequency, haplotype blocks, previous evidence, functionality in order to obtain a list of suitable SNPs for future studies that properly cover all possible genetic control of the HTR2A gene. Genetic association studies report conflicting and generally negative results. Most replicated data suggest C allele of the 102 T/C and Tyr452 variants as risk factor for psychosis and antipsychotic response, but the number of not replicating studies does not allow to draw any definite conclusion. Moreover their impact as risk factors is very small. In the other investigated psychiatric fields, evidence shows no involvement or at least a small and not replicated role for HTR2A gene variants. Conflicting and negative results could be due to a real marginal role of this receptor gene variants, or it could be caused by a lack of gene coverage of investigated SNPs. We suggest a wider investigation of the HTR2A gene to better understand its role in psychiatric disorders, preferably complemented with the use of proteomic or metabolomic approaches.
Export Options
About this article
Cite this article as:
Alessandro Serretti , Antonio Drago and Diana De Ronchi , HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies, Current Medicinal Chemistry 2007; 14 (19) . https://dx.doi.org/10.2174/092986707781368450
DOI https://dx.doi.org/10.2174/092986707781368450 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Targeting Nicotinic Receptors for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
Current Genomics Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship
Current Drug Metabolism Unraveling Monoamine Receptors Involved in the Action of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission in Prefrontal Cortex
Current Pharmaceutical Design Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry Conference Report (42nd Annual Meeting of the Italian Society of Neurology, 22-25 October 2011, Turin, Italy)
CNS & Neurological Disorders - Drug Targets Tardive Dyskinesia with Atypical Antipsychotic Drugs
Current Drug Therapy Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets Anti-NMDA Receptor Encephalitis in Psychiatry
Current Psychiatry Reviews Sleep in Interstitial Lung Disease
Current Respiratory Medicine Reviews Drug-Induced Impulse Control Disorders: A Review
Current Clinical Pharmacology Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Molecular Recognisation of 3a, 4-Dihydro-3-H-Indeno [1, 2-C] Pyrazole-2- Carboxamide/Carbothioamide Anticonvulsant Analogues Towards GABA-Aminotransferase- An in Silico Approach
Central Nervous System Agents in Medicinal Chemistry Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Optimized Trace Analysis of Verapamil in Biological Fluids Using Solvent Bar Micro Extraction Technique Coupled with HPLC-UV Detection
Current Analytical Chemistry Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets